La Roche-Posay Launches Mela B3 Double Dose With Melasyl

La Roche-Posay announced on May 22, 2026 the expansion of its Mela B3 hyperpigmentation line with a new Mela B3 Double Dose Discoloration Treatment formulated to address dark spots and visible aging on the face, neck, décolleté, and hands. The launch pairs 1% Melasyl, L'Oréal's patented melanin-precursor scavenger, with Proxylane in a single intensive treatment. **Key Takeaways** - La Roche-Posay announced the Mela B3 Double Dose Discoloration Treatment on May 22, 2026, expanding its Mela B3 hyperpigmentation franchise to include face, neck, décolleté, and hands. - The formula combines 1% Melasyl (INCI 2-mercaptonicotinoyl glycine), a thiopyridinone that scavenges melanin precursors before they form colored pigment, with Proxylane, a hydroxypropyl tetrahydropyrantriol developed for glycosaminoglycan support. - L'Oréal Laboratories screened more than 100,000 molecules over 18 years before selecting Melasyl, and has filed 23 patents covering the ingredient globally. - Melasyl's upstream mechanism is distinct from tyrosinase inhibitors like kojic acid, arbutin, and hydroquinone, which act on the enzyme that drives pigment synthesis rather than on its substrates. The brand confirmed the expansion in a PR Newswire statement issued the same day, alongside a partnership renewal with actress Keke Palmer as the franchise ambassador. A 2024 La Roche-Posay survey of 23,000 respondents found that nearly half of those living with pigmentary disorders reported a moderate to extremely large impact on quality of life, a data point the brand has cited as the rationale for continued investment in the category. ## How Melasyl Works Differently From the Tyrosinase Playbook For decades, the consumer hyperpigmentation toolkit has revolved around tyrosinase inhibition. Kojic acid, arbutin, azelaic acid, and prescription hydroquinone all act on the enzyme that converts L-tyrosine into the intermediate compounds that become melanin. Tranexamic acid, another commonly used pigmentation actor, modulates the plasminogen pathway and reduces inflammation-driven pigment signaling. Iron oxides in tinted sunscreen address pigmentation from the outside in by absorbing visible light. SkinCareful has covered the comparative evidence on [topical and oral tranexamic acid for melasma](https://skincareful.care/science/tranexamic-acid-topical-vs-oral-melasma/) and the [visible-light photochemistry behind iron oxide sunscreens](https://skincareful.care/science/iron-oxide-sunscreen-melasma-visible-light/) in prior coverage. Melasyl operates upstream. According to L'Oréal's published material on the molecule, the compound belongs to the thiopyridinone family and intercepts melanin precursors before they undergo enzymatic conversion into eumelanin and pheomelanin, the two pigment classes responsible for visible discoloration. Capturing precursors before they reach the colored stage is a mechanistically distinct lever from inhibiting the enzymatic step itself. L'Oréal disclosed that the ingredient is the result of 18 years of research and the screening of more than 100,000 candidate molecules, with 23 patents filed across global jurisdictions. The INCI designation is 2-mercaptonicotinoyl glycine, sometimes abbreviated 2-MNG. ## What Does Proxylane Add to the Formulation? Proxylane is the trade name for hydroxypropyl tetrahydropyrantriol, a glycoside developed by L'Oréal that has appeared in Lancôme and Vichy formulations as a glycosaminoglycan-support ingredient. In the Mela B3 Double Dose context, Proxylane is positioned to address the aging signs that frequently overlap with pigmentation on sun-exposed zones like the décolleté and dorsal hands. The brand frames the dual approach as "discoloration and signs of aging" within a single intensive treatment, rather than requiring users to layer a separate anti-aging product over a pigmentation actor. ## Why the Hands and Décolleté Expansion Matters The Mela B3 line first launched in 2024 with a face-focused serum and cleanser. The May 22 expansion explicitly extends the indication to neck, décolleté, and hands, regions where solar lentigines, often called age spots or sun spots, accumulate from decades of UV exposure. These zones are clinically significant for hyperpigmentation but commercially underserved. Most pigmentation treatments are formulated and marketed as facial products, leaving patients to either ration their facial actives down to the chest and hands or seek out separate, often less-active body formulations. La Roche-Posay's expanded use case acknowledges a treatment gap that dermatologists have long flagged. ## What This Launch Tells Us About the Pigmentation Category The Mela B3 expansion is one of the most visible commercial deployments of a non-tyrosinase, non-tranexamic-acid pigmentation actor in the mass-prestige skincare segment. For an industry that has cycled through the same handful of brightening ingredients for nearly thirty years, an ingredient with a genuinely novel mechanism and 18 years of platform investment behind it suggests that the precursor-scavenger pathway is being validated as a long-term category. The fact that a dermocosmetic brand owned by L'Oréal is the lead deployment vehicle, rather than a luxury or clinical line, signals an intention to seat Melasyl as a workhorse ingredient rather than a halo asset. For consumers evaluating dark-spot products, the practical implication is that the comparison set is widening. The question is no longer only "what concentration of niacinamide or vitamin C does this product contain," but also "does this product use a tyrosinase inhibitor, a melanin-precursor scavenger, an anti-inflammatory pigment modulator, or some combination of the three." The mechanistic vocabulary of pigmentation skincare is becoming more specific. ## What's Next for the Mela B3 Line and the Melasyl Category The Double Dose Discoloration Treatment is positioned as the most intensive product in the Mela B3 lineup to date, and La Roche-Posay has indicated that the franchise will continue to expand under the renewed Keke Palmer ambassadorship through 2026. Beyond La Roche-Posay, Melasyl is expected to appear in additional L'Oréal Group formulations across both the dermocosmetic and luxury divisions, given the 23-patent global filing footprint and the 18-year development runway. Independent clinical evaluation will be the next data point worth watching. Brand-sponsored efficacy claims established Melasyl's commercial trajectory, but peer-reviewed comparative trials measuring Melasyl against established tyrosinase inhibitors in standardized hyperpigmentation models would clarify how the precursor-scavenger approach actually performs head-to-head against the existing toolkit. Until that literature matures, the most defensible position for consumers is to treat Melasyl as a credible addition to the pigmentation category that merits trial, particularly in regimens that have plateaued on tyrosinase-targeted actives.